Misfolded insulin may be quietly driving diabetes

Groundbreaking research conducted by a collaborative team from the Sanford Burnham Prebys Medical Discovery Institute and the University of Michigan has illuminated new, crucial details about this destructive process. Their findings, published on June 1, 2026, in the esteemed Proceedings of the National Academy of Sciences, offer an unprecedented look into how insulin-producing cells meticulously coordinate protein folding and, critically, what transpires when this finely tuned system veers out of balance. This pivotal work strongly suggests that fortifying the cellular machinery responsible for accurate protein folding could represent a potent new strategy to shield these vulnerable cells from irreversible damage, potentially altering the trajectory of diabetes management and prevention.

The Mounting Crisis: Why Insulin-Producing Beta Cells Become Overwhelmed

Diabetes, particularly type 2 diabetes, is a global health crisis, affecting hundreds of millions worldwide. Its onset is often preceded by prediabetes, a state where blood sugar levels are elevated but not yet high enough to be classified as diabetes. Central to both conditions are the beta cells nestled within the islets of Langerhans in the pancreas. These remarkable cells serve as vigilant sentinels, constantly monitoring blood glucose levels. When glucose rises, such as after a meal, beta cells respond by dramatically increasing their production and secretion of insulin. This insulin acts as a key, unlocking cells throughout the body to absorb glucose from the bloodstream, thereby restoring blood sugar to a healthy, normal range.

However, in the context of prediabetes and advancing type 2 diabetes, the body’s tissues gradually become less responsive to insulin, a phenomenon known as insulin resistance. To compensate for this resistance and maintain normal blood glucose, beta cells are forced into overdrive, producing ever-increasing quantities of insulin. This relentless demand places immense stress on the cellular factories responsible for protein synthesis and folding, specifically the endoplasmic reticulum (ER). Over time, this chronic overexertion leads to beta cell exhaustion, dysfunction, and eventually, death, severely compromising the body’s ability to produce adequate insulin.

Previous scientific investigations have already established a critical link between this progressive decline in beta cell function and the misfolding of proinsulin, the precursor protein from which mature insulin is derived. Scientists had observed that improperly folded proinsulin aggregates within the ER, triggering a specific form of cellular distress known as ER stress, which is a hallmark of pancreatic beta cell pathology in diabetes. While this connection was clear, the precise molecular mechanisms—specifically, which additional proteins govern this intricate folding process and how they collaborate to ensure proinsulin integrity—remained largely enigmatic. Unraveling these details was the primary objective of the Kaufman lab and their collaborators.

"We knew that the intricate system for preventing proinsulin misfolding depended heavily on a master chaperone protein called binding immunoglobulin protein, or BiP, along with a cadre of its cochaperones," explained Randal J. Kaufman, PhD, a distinguished professor in the Center for Metabolic and Liver Diseases at Sanford Burnham Prebys and the senior and corresponding author of this landmark study. "Our overarching goal was to meticulously examine how these critical partner proteins coordinate the precise folding of proinsulin and efficiently remove any misfolded mistakes. These steps, we understood, are absolutely essential for maintaining the robust health and long-term viability of insulin-producing beta cells."

Unraveling the Molecular Choreography: Tracking a Key Protein Inside Beta Cells

To meticulously dissect the complex interactions involving BiP, the researchers employed a sophisticated genetic engineering approach. They genetically modified mice such that the BiP protein specifically within their beta cells carried an additional, unique amino acid chain: a peptide tag. This tag consisted of three tandem copies of an eight-amino-acid sequence, famously known as a 3xFLAG-tag. This innovative molecular beacon acted as a precise identifier, allowing scientists to detect, track, and isolate BiP and its associated protein complexes with unprecedented ease and accuracy during their biochemical experiments. This enabled them to capture fleeting interactions and identify critical partners that would otherwise be undetectable.

The meticulous analysis of these tagged BiP complexes yielded a profound insight, pointing toward an especially crucial and previously underestimated role for p58^IPK, one of BiP’s many cochaperone proteins. Cochaperones are accessory proteins that assist chaperones like BiP, often by modulating their activity, guiding them to specific substrates, or facilitating their ATP hydrolysis cycle, which is essential for their function.

To rigorously test the significance of p58^IPK, the researchers conducted targeted genetic experiments. When they genetically removed p58^IPK from two distinct beta cell lines—cellular models specifically engineered to mimic pancreatic beta cells—the consequences were stark: misfolded proinsulin accumulated at significantly higher levels. This indicated a severe breakdown in the cell’s quality control system. To validate these in vitro findings, the team extended their investigation to in vivo models, examining mice that were genetically engineered not to produce p58^IPK. These animal models corroborated the cellular data, showing similar evidence of cellular distress. Critically, their beta cells produced substantially smaller amounts of both proinsulin and, consequently, mature insulin, demonstrating a direct functional impact on the very output of these vital cells. This dual approach—combining cell line studies with animal models—provided robust evidence for p58^IPK‘s essential role.

The Symphony of Collaboration: BiP and p58^IPK Must Work Together

The investigative team then sought to understand the nature of the relationship between p58^IPK and BiP. Was p58^IPK merely an accessory, or was it an indispensable partner? They performed rescue experiments, reintroducing p58^IPK into one of the previously modified cell lines that lacked it. The results were compelling: restoring p58^IPK dramatically improved the cells’ intrinsic ability to properly fold and efficiently transport proinsulin through the ER, while simultaneously reducing the detrimental accumulation of improperly folded copies. This demonstrated that p58^IPK was not just involved but actively required for efficient proinsulin quality control.

However, a crucial caveat emerged: these remarkable improvements were not observed unless BiP, the master chaperone, was also present and functional. This finding underscored that p58^IPK, while vital, could not independently assume BiP’s central and overarching role in protein folding. Their roles were complementary and interdependent, rather than interchangeable.

To further probe this synergy, the researchers investigated whether simply increasing the abundance of BiP could compensate for the absence of p58^IPK. When cells were engineered to produce extra BiP but still lacked p58^IPK, they exhibited only modest, limited gains in proinsulin folding efficiency and its subsequent movement out of the cell. The improvements were statistically and functionally substantially greater, however, when both proteins—BiP and p58^IPK—were present and functioning at their normal, physiological levels. This provided irrefutable evidence that BiP requires its cochaperone p58^IPK to operate optimally in the context of proinsulin folding.

"Like a single tennis player trying valiantly to play a doubles match, we found conclusively that BiP cannot just go it alone in maintaining the proper folding of proinsulin," articulated Insook Jang, PhD, a highly skilled staff scientist in the Kaufman lab and the lead author of the published manuscript. Her analogy powerfully conveys the necessity of this molecular partnership, highlighting that the complexity of cellular processes often relies on precisely coordinated team efforts rather than individual heroic proteins. The interplay between chaperones and cochaperones ensures efficiency, specificity, and adaptability in the face of diverse cellular demands and stresses.

Beyond BiP and p58^IPK, the investigators also successfully identified additional partner proteins that are intricately involved in the multifaceted processes of folding and transporting proinsulin, as well as detecting and effectively managing its misfolded versions. This discovery opens new avenues for research, as more work will be required to precisely delineate how each of these newly identified proteins influences overall insulin production and, critically, the nuanced progression of diabetes. These findings paint a picture of a sophisticated, multi-component quality control system, where multiple players contribute to the delicate balance of protein homeostasis.

"Our comprehensive studies distinctly highlight that proinsulin folding, a process paramount to beta cell function, is acutely vulnerable to many of the same pervasive cellular stresses that are now well-established causes of beta cell failure in type 2 diabetes," Dr. Kaufman emphasized. This direct connection between a specific molecular defect and a broader pathological process solidifies the importance of their findings in understanding the fundamental mechanisms underlying the disease.

A Potential New Diabetes Treatment Strategy: Targeting the Root Cause

The implications of this research extend far beyond fundamental cellular biology; they point toward a paradigm shift in therapeutic strategies for diabetes. Most existing diabetes medications, while effective in managing symptoms, do not directly address or correct the underlying protein-folding problems that are now increasingly understood to contribute significantly to beta cell failure. Instead, current therapies primarily operate by helping peripheral tissues absorb more glucose from the bloodstream, thereby lowering blood sugar, or by stimulating the pancreas to release more insulin, often at the cost of further beta cell strain.

Crucially, no current therapies are specifically designed or employed to improve proinsulin folding quality in a targeted manner, with the explicit goal of preserving the long-term health and functional capacity of pancreatic beta cells. This represents a significant gap in the therapeutic landscape. The ability to intervene at this fundamental level—at the very point where insulin begins its journey from a precursor protein—offers a tantalizing prospect for disease modification rather than just symptom management.

"If we can systematically learn how to precisely influence and enhance the coordinated activity of BiP, recognizing its newfound role as a pivotal regulator of proinsulin folding, we may indeed uncover a profoundly promising treatment strategy for intervening early in the disease process," Dr. Kaufman mused, looking toward the future. Such an intervention could potentially prevent or substantially reduce the chronic, cumulative damage to insulin-producing cells that currently defines the relentless progression of diabetes. This could involve developing small molecules that stabilize the BiP-p58^IPK complex, enhance BiP’s chaperone activity, or modulate the expression levels of these key proteins.

The identification of p58^IPK as a critical partner to BiP in this context provides a concrete target for drug discovery. Therapeutics aimed at optimizing the function of this protein partnership could bolster the beta cell’s inherent capacity to produce properly folded proinsulin, thereby reducing ER stress, preserving beta cell mass, and extending their functional lifespan. This approach offers the exciting potential to move beyond simply managing blood glucose levels and instead, to protect the very cells whose failure underpins the chronic nature of diabetes.

This collaborative work, a testament to inter-institutional scientific endeavor, also saw significant contributions from Alec Duffey and Pamela Itkin-Ansari at Sanford Burnham Prebys, alongside Peter Arvan at the University of Michigan. The comprehensive study was made possible through vital financial support from several prestigious organizations, including the National Institutes of Health (specifically the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Cancer Institute), as well as Breakthrough T1D (formerly known as JDRF), underscoring the broad relevance and potential impact of this research across metabolic and immunological disciplines. These findings represent a significant leap forward in understanding the molecular underpinnings of diabetes and open a promising new frontier for therapeutic intervention, potentially offering a brighter future for millions living with, or at risk of, this pervasive disease.